Abstract
In The Lancet, Yeming Wang and colleagues1 report a randomised trial of remdesivir (200 mg on day 1 followed by 100 mg on days 2–10, in single daily infusions) versus placebo for adults with severe coronavirus disease 2019 (COVID-19) in ten hospitals in Wuhan, China. The authors report on 236 patients (140 [59%] men and 96 [41%] women; median age 65 years [IQR 56–71]), with inconclusive findings on the primary outcome of time to clinical improvement, defined as a two-point improvement on a 6-point ordinal scale,2 a hazard ratio of 1·23 (95% CI 0·87–1·75; favouring remdesivir), and median observation times of 21 days (IQR 13–28) in the remdesivir group versus 23 days (15–28) in the placebo group (a non-significant difference).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have